Free Trial
LON:CEL

Celadon Pharmaceuticals (CEL) Share Price, News & Analysis

Celadon Pharmaceuticals logo
GBX 20 +2.50 (+14.29%)
(As of 12/24/2024 05:29 AM ET)

About Celadon Pharmaceuticals Stock (LON:CEL)

Key Stats

Today's Range
17.50
20
50-Day Range
11
32
52-Week Range
11
122.50
Volume
231 shs
Average Volume
77,010 shs
Market Capitalization
£13.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder. For further information please visit our website www.celadonpharma.com

Receive CEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CEL Stock News Headlines

70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!
Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.
Celadon Pharmaceuticals Plc (CEL.L)
See More Headlines

CEL Stock Analysis - Frequently Asked Questions

Celadon Pharmaceuticals' stock was trading at GBX 115 on January 1st, 2024. Since then, CEL stock has decreased by 82.6% and is now trading at GBX 20.
View the best growth stocks for 2024 here
.

Shares of CEL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Celadon Pharmaceuticals investors own include AutoZone (AZO), Bahamas Petroleum (BPC), Intel (INTC), TJX Companies (TJX), Abacus Health Products (ABAHF), Avino Silver & Gold Mines (ASM) and Avino Silver & Gold Mines (ASM).

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Communication
CIK
N/A
Fax
N/A
Employees
2,780
Year Founded
N/A

Profitability

Net Income
£-5,230,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£11,258.00
Cash Flow
GBX 6.55 per share
Book Value
GBX 4 per share

Miscellaneous

Free Float
N/A
Market Cap
£13.77 million
Optionable
Not Optionable
Beta
-0.26
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (LON:CEL) was last updated on 12/25/2024 by MarketBeat.com Staff
From Our Partners